Filtered By:
Therapy: Cancer Therapy

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 4168 results found since Jan 2013.

U.S. FDA approves Foundation Medicine ’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib)
FoundationOneCDx can now be used to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solidtumours for whom treatment withRozlytrek may be appropriateThis approval marks the first and only companion diagnostic indication forRozlytrek, and another important milestone intumour-agnostic approaches for people living with rare cancersRoche is a leader in drivingpersonalised healthcare around the world through validated diagnostic tools, genomic insights and a continued focus on drug developmentBasel, 9 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that ...
Source: Roche Media News - June 9, 2022 Category: Pharmaceuticals Source Type: news

Traditional Chinese medicine as complementary treatment for hepatocellular carcinoma
Conclusions: The prognostics and survival rate of patients with hepatocellular carcinomas may be enhanced by targeted treatment of this major cell population. Traditional Chinese medicine has shown benefits to both tumour progression and drug resistance, as well as to the prevention of recurrence and metastasis. [Ethiop. J. Health Dev. 2021; 35(4): 320-327]Key words: Hepatocellular carcinoma, Chinese medicine, herbal treatment, squamous cell carcinoma, cancer stem cells.
Source: Ethiopian Journal of Health Development - November 25, 2021 Category: African Health Authors: Jiao Kede, Bie Limei, Yin XiLing, Yu Liqiu Source Type: research

PHARMACOGENOMICS: Driving Personalized Medicine
Pharmacol Rev. 2023 Mar 16:PHARMREV-AR-2022-000810. doi: 10.1124/pharmrev.122.000810. Online ahead of print.ABSTRACTPersonalized medicine tailors therapies, disease prevention, and health maintenance to the individual, with pharmacogenomics serving as a key tool to improve outcomes and prevent adverse effects. Advances in genomics have transformed pharmacogenetics, traditionally focused on single gene-drug pairs, into pharmacogenomics, encompassing all 'omics' fields, e.g., proteomics, transcriptomics, metabolomics, and metagenomics. This review summarizes basic genomics principles relevant to translation into therapies, a...
Source: Pharmacological Reviews - March 17, 2023 Category: Drugs & Pharmacology Authors: Wolfgang Sadee Danxin Wang Katherine Hartmann Amanda Ewart Toland Source Type: research

We and They in the House of Healing: Debate Among Arab Complementary Medicine Practitioners on an Integrative Versus Alternative Approach to Supportive Cancer Care
Conclusions. The majority of Arab CTM therapists support integration of their treatments with the conventional system, but in practice, they are not sure how to bring about this change or create a parallel model in which 2 different systems are active, but not integrated. Our findings emphasized the need to promote doctor–CTM practitioner communication based on structured referral and bidirectional consultation. Moreover, we recommend intensifying research on the efficacy and safety of CTM in the Middle East and the potential role in promoting culture-based supportive care.
Source: Integrative Cancer Therapies - October 17, 2013 Category: Cancer & Oncology Authors: Popper-Giveon, A., Schiff, E., Ben-Arye, E. Tags: Articles Source Type: research

Just caring: Assessing the ethical and economic costs of personalized medicine.
Abstract Personalized medicine has been touted as a revolutionary form of cancer care. It has been portrayed as precision medicine, targeting with deadly accuracy cancer cells and sparing patients the debilitating broad-spectrum side effects of more traditional forms of cancer therapy. But personalized medicine still has its costs to patients and society, both moral and economic costs. How to recognize and address those issues will be the focus of this essay. We start with these questions: Does everyone faced with cancer have a moral right to the most effective cancer care available, no matter what the cost, no ma...
Source: Urologic Oncology - January 27, 2014 Category: Urology & Nephrology Authors: Fleck LM Tags: Urol Oncol Source Type: research

Cancer Prevention and Therapy: Integrating Traditional Korean Medicine Into Modern Cancer Care
In spite of billions of dollars spent on cancer research each year, overall cancer incidence and cancer survival has not changed significantly in the last half century. Instead, the recent projection from the World Health Organization suggests that global cancer incidence and death is expected to double within the next decade. This requires an "out of the box" thinking approach. While traditional medicine used for thousands of years is safe and affordable, its efficacy and mechanism of action are not fully reported. Demonstrating that traditional medicine is efficacious and how it works can provide a "bed to bench" and "be...
Source: Integrative Cancer Therapies - July 8, 2014 Category: Cancer & Oncology Authors: Yoon, S. W., Jeong, J. S., Kim, J. H., Aggarwal, B. B. Tags: Articles Source Type: research

Complementary and alternative medicine (CAM) in obstetrics and gynaecology: a survey of office-based obstetricians and gynaecologists regarding attitudes towards CAM, its provision and cooperation with other CAM providers in the state of Hesse, Germany
Conclusions The analysis shows that there is much cooperation in the field of CAM. Comparison between physicians’ perceived efficacy of CAM methods and objective findings shows that there is a need for the provision of valid information in the field.
Source: Archives of Gynecology and Obstetrics - November 4, 2014 Category: OBGYN Source Type: research

Unique roles of nanotechnology in medicine and cancer-II
F Alam, M Naim, M Aziz, N YadavIndian Journal of Cancer 2015 52(1):1-9Applications of nanotechnology in medicine and cancer are becoming increasingly popular. Common nanomaterials and devices applicable in cancer medicine are classifiable as liposomes, polymeric-micelles, dendrimers, nano-cantilevers, carbon nanotubes, quantum dots, magnetic-nanoparticles, gold nanoparticles (AuNPs) and certain miscellaneous nanoparticles. Here, we present review of the structure, function and utilities of the various approved, under trial and pretrial nanodevices applicable in the cancer care and medicine. The liposomes are phospholipid-v...
Source: Indian Journal of Cancer - February 3, 2016 Category: Cancer & Oncology Authors: F AlamM NaimM AzizN Yadav Source Type: research

Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.
Abstract Cancer therapy agents have been used extensively as cytotoxic drugs against tissue or organ of a specific type of cancer. With the better understanding of molecular mechanisms underlying carcinogenesis and cellular events during cancer progression and metastasis, it is now possible to use targeted therapy for these molecular events. Targeted therapy is able to identify cancer patients with dissimilar genetic defects at cellular level for the same cancer type and consequently requires individualized approach for treatment. Cancer therapy begins to shift steadily from the traditional approach of "one regime...
Source: Genomics Proteomics ... - August 13, 2017 Category: Genetics & Stem Cells Authors: Kamel HFM, Al-Amodi HSAB Tags: Genomics Proteomics Bioinformatics Source Type: research

Integration of Homeopathy and Complementary Medicine in the Tuscan Public Health System and the Experience of the Homeopathic Clinic of the Lucca Hospital.
CONCLUSIONS:  These results suggest that homeopathy can effectively be integrated with allopathic medicine and that the Tuscan experience could provide a useful reference for developing national and European regulations on the use of CM and homeopathy in public healthcare. PMID: 29549880 [PubMed - as supplied by publisher]
Source: Homeopathy - March 17, 2018 Category: Complementary Medicine Authors: Rossi E, Di Stefano M, Picchi M, Panozzo MA, Noberasco C, Nurra L, Baccetti S Tags: Homeopathy Source Type: research

Systems Biology, Systems Medicine, Systems Pharmacology: The What and The Why.
Abstract Systems biology is today such a widespread discipline that it becomes difficult to propose a clear definition of what it really is. For some, it remains restricted to the genomic field. For many, it designates the integrated approach or the corpus of computational methods employed to handle the vast amount of biological or medical data and investigate the complexity of the living. Although defining systems biology might be difficult, on the other hand its purpose is clear: systems biology, with its emerging subfields systems medicine and systems pharmacology, clearly aims at making sense of complex observ...
Source: Acta Biotheoretica - May 9, 2018 Category: Biomedical Science Authors: Stéphanou A, Fanchon E, Innominato PF, Ballesta A Tags: Acta Biotheor Source Type: research

Basket Trials and the MD Anderson Precision Medicine Clinical Trials Platform
Precision medicine incorporates information regarding tumor biology involved in patients' carcinogenesis and individualized treatment of patients using drugs that inhibit the molecular basis of their disease. Implementation of precision medicine accelerated the drug approval process, translating discoveries in basic science and biotechnology into patient care. Clinical trials with innovative or adaptive design including “basket” and “umbrella” trials explore personalized therapies against in selected tumor types and/or across tumor types. In 2007, we started the Initiative for Molecular Profiling and Advanced Cance...
Source: The Cancer Journal - July 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research

Cancers, Vol. 14, Pages 5310: Quality of Life (QoL) of Children and Adolescents Participating in a Precision Medicine Trial for High-Risk Childhood Cancer
We examined QoL among patients enrolled in PRISM, the Zero Childhood Cancer Program’s precision medicine trial for high-risk childhood cancer. We assessed patient QoL via self-report (aged 12–17 years) and parent-proxy (aged 4–17 years) completion of the EQ-5D-Y. We analysed data using descriptive statistics and regression models. Patients (n = 23) and parents (n = 136) provided data after trial enrolment and following receipt of trial results and treatment recommendations (n = 8 patients, n = 84 parents). At enrolment, most patients were experiencing at least some difficulty acros...
Source: Cancers - October 28, 2022 Category: Cancer & Oncology Authors: Kate Hetherington Claire E. Wakefield Kavitha P. K. Kunalan Mark W. Donoghoe Brittany C. McGill Joanna E. Fardell Rebecca Daly Rebecca J. Deyell David S. Ziegler Tags: Article Source Type: research

Just caring: Assessing the ethical and economic costs of personalized medicine
Abstract: Personalized medicine has been touted as a revolutionary form of cancer care. It has been portrayed as precision medicine, targeting with deadly accuracy cancer cells and sparing patients the debilitating broad-spectrum side effects of more traditional forms of cancer therapy. But personalized medicine still has its costs to patients and society, both moral and economic costs. How to recognize and address those issues will be the focus of this essay. We start with these questions: Does everyone faced with cancer have a moral right to the most effective cancer care available, no matter what the cost, no matter whe...
Source: Urologic Oncology: Seminars and Original Investigations - January 21, 2014 Category: Urology & Nephrology Authors: Leonard M. Fleck Tags: Seminar Articles Source Type: research

Integrating genomics into clinical oncology: Ethical and social challenges from proponents of personalized medicine.
CONCLUSIONS: These specific concerns are not unique to oncology, or even genomics. However, those most invested in the success of PM view oncologists' responses to these challenges as precedent setting because oncology is farther along the path of clinical integration of genomic technologies than other fields of medicine. This study illustrates that the rapid emergence of PM approaches in clinical oncology provides a crucial lens for identifying and managing potential frictions and pitfalls that emerge as health care paradigms shift in these directions. PMID: 24445286 [PubMed - in process]
Source: Urologic Oncology - January 27, 2014 Category: Urology & Nephrology Authors: McGowan ML, Settersten RA, Juengst ET, Fishman JR Tags: Urol Oncol Source Type: research